Stock comparison
Genmab A/S
Globus Medical
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
GMED
Globus Medical
Market cap
$11.44B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | GMED | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 58C | GMAB |
| Benjamin Graham | 64C | 65B | GMED |
| Philip Fisher | 48D | 70C | GMED |
| Peter Lynch | 25F | 63C | GMED |
| Joel Greenblatt | 76B | 45D | GMAB |
| Charlie Munger | 68C | 51D | GMAB |
| Terry Smith | 71C | 56D | GMAB |
Side-by-side metrics
| Metric | GMAB | GMED |
|---|---|---|
| Market cap | $16.5B | $11.44B |
| P/E (TTM) | 6.2x | 17.7x |
| EV/EBIT | 12.0x | 20.6x |
| ROIC (TTM) | 43.78% | 9.72% |
| Gross margin | 93.88% | 67.86% |
| Net margin | 18.23% | 18.92% |
| Revenue CAGR 5y | -18.45% | 32.34% |
| EPS CAGR 5y | -23.48% | 28.06% |
| Debt / Equity | 0.1x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- ROIC (TTM)43.78%vs 9.72%+78%
- P/E (TTM)6.2xvs 17.7x+65%
- EV/EBIT12.0xvs 20.6x+42%
- Market cap$16.5Bvs $11.44B+31%
GMED leads on
- EPS CAGR 5y28.06%vs -23.48%+184%
- Revenue CAGR 5y32.34%vs -18.45%+157%
- Debt / Equity0.0xvs 0.1x+67%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.